| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $50M | ||
| $50M |
Buys | $58,036,053 | 36 | 92 |
Sells | $1,337,214 | 3 | 8 |
| EcoR1 Capital, LLC | 36 | $58.04M | 0 | $0 | $58.04M | |
| Smith Jeffrey T L | EVP & Chief Medical Officer | 0 | $0 | 1 | $165,807 | $-165,807 |
| Moore Paul Andrew | Chief Scientific Officer | 0 | $0 | 1 | $316,391 | $-316,391 |
| Galbraith Kenneth | Chair & CEO | 0 | $0 | 1 | $855,017 | $-855,017 |
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Over the last 12 months, insiders at Zymeworks Inc. have bought $58.04M and sold $1.34M worth of Zymeworks Inc. stock.
On average, over the past 5 years, insiders at Zymeworks Inc. have bought $35.87M and sold $2.74M worth of stock each year.
Highest buying activity among insiders over the last 12 months: EcoR1 Capital, LLC () — $58.04M.
The last purchase of 5,919 shares for transaction amount of $69,738 was made by EcoR1 Capital, LLC () on 2025‑05‑19.
| 2025-05-19 | EcoR1 Capital, LLC | 5,919 0.0085% | $11.78 | $69,738 | +6.04% | |||
| 2025-05-15 | EcoR1 Capital, LLC | 49,502 0.0704% | $11.43 | $565,847 | +10.67% | |||
| 2025-04-17 | EcoR1 Capital, LLC | 54,760 0.0869% | $11.52 | $630,819 | +6.40% | |||
| 2025-04-16 | EcoR1 Capital, LLC | 73,953 0.1138% | $11.16 | $825,589 | +8.40% | |||
| 2025-04-04 | EcoR1 Capital, LLC | 196,438 0.288% | $11.17 | $2.19M | +7.31% | |||
| 2025-04-03 | EcoR1 Capital, LLC | 120,770 0.1749% | $11.84 | $1.43M | -0.04% | |||
| 2025-04-02 | EcoR1 Capital, LLC | 74,360 0.1062% | $11.85 | $881,017 | -1.43% | |||
| 2025-04-01 | EcoR1 Capital, LLC | 48,658 0.0698% | $11.60 | $564,647 | +1.12% | |||
| 2025-03-31 | EcoR1 Capital, LLC | 4,397 0.0062% | $11.75 | $51,658 | -1.34% | |||
| 2025-03-26 | EcoR1 Capital, LLC | 43,848 0.0625% | $12.24 | $536,857 | -4.21% | |||
| 2025-03-25 | EcoR1 Capital, LLC | 53,501 0.0775% | $12.91 | $690,452 | -6.95% | |||
| 2025-03-24 | EcoR1 Capital, LLC | 22,689 0.0327% | $13.08 | $296,847 | -8.70% | |||
| 2025-03-21 | EcoR1 Capital, LLC | 31,033 0.0448% | $12.78 | $396,518 | -6.29% | |||
| 2025-03-20 | EcoR1 Capital, LLC | 73,476 0.1056% | $12.93 | $949,883 | -7.66% | |||
| 2025-03-19 | EcoR1 Capital, LLC | 58,306 0.0828% | $12.64 | $737,233 | -6.49% | |||
| 2025-03-18 | EcoR1 Capital, LLC | 113,880 0.1678% | $12.65 | $1.44M | -2.84% | |||
| 2025-03-17 | EcoR1 Capital, LLC | 56,277 0.0787% | $12.23 | $688,465 | -4.45% | |||
| 2025-03-13 | EcoR1 Capital, LLC | 468,356 0.6696% | $12.48 | $5.85M | -3.11% | |||
| 2025-03-12 | EcoR1 Capital, LLC | 292,934 0.4199% | $12.25 | $3.59M | -0.83% | |||
| 2025-03-11 | EcoR1 Capital, LLC | 320,690 0.4528% | $11.49 | $3.69M | +4.23% |
| EcoR1 Capital, LLC | 17883908 25.6645% | $225.87M | 45 | 0 | <0.0001% | |
| Galbraith Kenneth | Chair & CEO | 47543 0.0682% | $600,468.09 | 0 | 3 | |
| Moore Paul Andrew | Chief Scientific Officer | 14741 0.0212% | $186,178.83 | 0 | 3 | |
| Smith Jeffrey T L | EVP & Chief Medical Officer | 8890 0.0128% | $112,280.70 | 0 | 1 | |
| Redmile Group, LLC | 10 percent owner | 6075918 8.7193% | $76.74M | 1 | 0 | +63.8% |
| LILLY ELI & CO | 10 percent owner | 2898647 4.1597% | $36.61M | 0 | 17 | |
| Tehrani Ali | Chief Executive Officer | 260325 0.3736% | $3.29M | 1 | 6 | +12.44% |
| Polverino Anthony J. | Chief Scientific Officer | 30979 0.0445% | $391,264.77 | 0 | 1 | |
| Klompas Neil A | President & COO | 17032 0.0244% | $215,114.16 | 0 | 5 | |
| Josephson Neil | Chief Medical Officer | 14449 0.0207% | $182,490.87 | 1 | 1 | <0.0001% |
| Cox Troy | director | 7500 0.0108% | $94,725.00 | 1 | 0 | <0.0001% |
| Astle Christopher | SVP & Chief Financial Officer | 6503 0.0093% | $82,132.89 | 0 | 3 | |
| HAUSMAN DIANA | Chief Medical Officer | 5377 0.0077% | $67,911.51 | 0 | 5 | |
| O'Driscoll Kathryn | Chief People Officer | 5003 0.0072% | $63,187.89 | 0 | 2 | |
| Priour James | Chief Commercial Officer | 2003 0.0029% | $25,297.89 | 0 | 1 | |
| Poon David Kai Yuen | See Remarks | 0 0% | $0 | 0 | 1 |
$3,596,906 | 112 | 13.42% | $921.06M | |
$8,217,280 | 112 | 46.33% | $1.02B | |
$1,101,324,300 | 58 | 37.37% | $863.71M | |
$571,084,134 | 44 | 4.33% | $901.08M | |
$107,495 | 42 | 44.54% | $770.91M | |
$149,456,352 | 27 | -8.77% | $1.04B | |
$7,598,498 | 27 | 34.68% | $871.44M | |
$54,828,550 | 26 | -13.88% | $934.98M | |
$49,750,490 | 17 | 37.19% | $760.97M | |
$4,210,269 | 14 | -15.87% | $768.32M | |
$152,858,569 | 14 | -4.66% | $991.27M | |
Zymeworks Inc. (ZYME) | $50,317,062 | 13 | -3.69% | $880.1M |
$9,976,473 | 12 | 29.52% | $875.26M | |
$2,859,892 | 10 | 29.21% | $833.8M | |
$20,499,451 | 9 | 71.54% | $824.32M | |
$1,229,547 | 7 | 11.98% | $987.22M | |
$46,235,722 | 6 | -31.77% | $994.4M | |
$19,420,853 | 5 | 4.35% | $785.77M | |
$7,605,533 | 5 | 17.10% | $894.86M |
| Increased Positions | 94 | +47.72% | 11M | +15.97% |
| Decreased Positions | 83 | -42.13% | 5M | -7.98% |
| New Positions | 32 | New | 2M | New |
| Sold Out Positions | 20 | Sold Out | 1M | Sold Out |
| Total Postitions | 208 | +5.58% | 72M | +7.99% |
| Ecor1 Capital, Llc | $194,764.00 | 21.47% | 15.03M | +2M | +11.84% | 2024-12-31 |
| Redmile Group, Llc | $62,732.00 | 6.92% | 4.84M | -261,448 | -5.13% | 2024-12-31 |
| Bvf Inc/Il | $55,844.00 | 6.16% | 4.31M | -299,000 | -6.49% | 2024-12-31 |
| Morgan Stanley | $54,451.00 | 6% | 4.2M | -905,432 | -17.73% | 2024-12-31 |
| Blackrock, Inc. | $52,999.00 | 5.84% | 4.09M | -95,535 | -2.28% | 2025-03-31 |
| Rubric Capital Management Lp | $50,769.00 | 5.6% | 3.92M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $32,313.00 | 3.56% | 2.49M | -365,226 | -12.78% | 2024-12-31 |
| Bnp Paribas Asset Management Holding S.A. | $27,704.00 | 3.05% | 2.14M | +192,162 | +9.88% | 2024-12-31 |
| Perceptive Advisors Llc | $27,605.00 | 3.04% | 2.13M | -50,000 | -2.29% | 2024-12-31 |
| Deutsche Bank Ag | $20,046.00 | 2.21% | 1.55M | +17,849 | +1.17% | 2024-12-31 |